Sep. 30 at 7:23 PM
Zoetis Inc shares rose Tuesday after the U.S. FDA granted conditional approval for the company’s drug, Dectomax-CA1, to prevent and treat New World Screwworm (NWS) infestations in cattle. The injectable, containing doramectin, is the first U.S.-approved treatment for NWS, preventing larval infestations and reinfestation for up to 21 days.
FDA Commissioner Marty Makary highlighted the urgency for farmers to access tools against NWS, noting this conditional approval addresses a serious animal health need while allowing Zoetis to collect further efficacy data. Dectomax-CA1 shares its active ingredient with Zoetis’ existing Dectomax, used for other nematodes and arthropod parasites in cattle and swine.
$ZTS